Clinical Trials Browser

INDUSTRY × cediranib × Genitourinary × Clear all

NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms